Physiological studies of placebo-mediated suggestion have been recently performed beyond their traditional clinical context of pain and analgesia. Various neurotransmitter systems and immunological modulators have been used in successful placebo suggestions, including Dopamine, Cholecystokinin and, most extensively, opioids. We adhered to an established conceptual framework of placebo research and used the l-opioid-antagonist Naloxone to test the applicability of this framework within a cognitive domain (e.g. memory) in healthy volunteers. Healthy men (n = 62, age 29, SD = 9) were required to perform a task-battery, including standardized and custom-designed memory tasks, to test short-term recall and delayed recognition. Tasks were performed twice, before and after intravenous injection of either NaCl (0.9%) or Naloxone (both 0.15 mg/kg), in a double-blind setting. While one group was given neutral information (SÀ), the other was told that it might receive a drug with suspected memory-boosting properties (S+). Objective and subjective indexes of memory performance and salivary cortisol (as a stress marker) were recorded during both runs and differences between groups were assessed. Short-term memory recall, but not delayed recognition, was objectively increased after placebo-mediated suggestion in the NaCl-group. Naloxone specifically blocked the suggestion effect without interfering with memory performance. These results were not affected when changes in salivary cortisol levels were considered. No reaction time changes, recorded to uncover unspecific attentional impairment, were seen.
Placebo Suggestion Working memory Short-term recall Naloxone Opioids a b s t r a c t Physiological studies of placebo-mediated suggestion have been recently performed beyond their traditional clinical context of pain and analgesia. Various neurotransmitter systems and immunological modulators have been used in successful placebo suggestions, including Dopamine, Cholecystokinin and, most extensively, opioids. We adhered to an established conceptual framework of placebo research and used the l-opioid-antagonist Naloxone to test the applicability of this framework within a cognitive domain (e.g. memory) in healthy volunteers. Healthy men (n = 62, age 29, SD = 9) were required to perform a task-battery, including standardized and custom-designed memory tasks, to test short-term recall and delayed recognition. Tasks were performed twice, before and after intravenous injection of either NaCl (0.9%) or Naloxone (both 0.15 mg/kg), in a double-blind setting. While one group was given neutral information (SÀ), the other was told that it might receive a drug with suspected memory-boosting properties (S+). Objective and subjective indexes of memory performance and salivary cortisol (as a stress marker) were recorded during both runs and differences between groups were assessed. Short-term memory recall, but not delayed recognition, was objectively increased after placebo-mediated suggestion in the NaCl-group. Naloxone specifically blocked the suggestion effect without interfering with memory performance. These results were not affected when changes in salivary cortisol levels were considered. No reaction time changes, recorded to uncover unspecific attentional impairment, were seen.
Placebo-mediated suggestion produced a training-independent, objective and Naloxone-sensitive increase in memory performance. These results indicate an opioid-mediated placebo effect within a circumscribed cognitive domain in healthy volunteers.
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Introduction
An ongoing challenge facing research on the placebo effect is how to properly disentangle its subjective and objective components (Harrington, 1999 (Harrington, , 2008 Moerman, 2002) . Within clinical contexts in particular, conceptual ambiguities related to this problem often persist, hindering proper evaluation of standard biomedical therapeutic interventions, and presenting difficulties for the assessment, appreciation and harnessing of the power of placebo effects (Benedetti, 2009; Frank, 1993; Kradin, 2008) . (For a perspective on how objectivity and subjectivity have come have become interrelated in modern science see Daston and Galison (2007) . For a review of the issues relating to objectivity within contemporary biomedical academia (Greene, 2007; Lakoff, 2006; Marks, 1997; Relman, 2007) . Within the field of placebo research, endogenous opioids were the first neurobiological substrates consistently enlisted as a physiological mediator of the placebo effect -when the administration of the opioid-antagonist Naloxone was shown to reduce placebo-mediated analgesia (Levine, Gordon, & Fields, 1978) . Since then, placebo research has expanded enormously and opioids continue to play a prominent role (Price, Finniss, & Benedetti, 2008; Zubieta & Stohler, 2009) . For example, brain-imaging studies have begun to specify the role of opioids in placebo processes by localizing placebo-induced functional changes in opioid-signalling in the brain (Zubieta et al., 2005) . Such studies have begun to model the functional anatomy of multiple involved areas in the cerebral cortex, the midbrain and the basal ganglia involved during placebo-mediated interactions (Faria, Fredrikson, & Furmark, 2008; Mayberg et al., 2002; Wager, Scott, & Zubieta, 2007) . They have also been able to account for endophenotypical
